Biotech and pharmaceutical SPAC Genesis Unicorn Capital prices $75 million IPO

Genesis Unicorn Capital, a blank check company targeting the biotech and pharmaceutical sectors, raised $75 million by offering 7.5 million units at $10. Each unit consists of one share of common stock and one warrant, exercisable at $11.50.

The company is led by CEO Adeoye Olukotun, who is a Mayo Clinic trained cardiologist and currently serves as the CEO of CR Strategies; CFO, President, and Director Samuel Lui, the founder and Managing Director of private investment firm LV Capital; and COO Juan Fernandez, who most recently served as the General Manager of Chassis Brakes International Spain, part of Hitachi Automotive Systems.

Genesis Unicorn Capital plans to target businesses at the intersection of the healthcare and technology industries, specifically within the biotechnology and pharmaceutical sectors, focusing on those with total enterprise values between $200 million and $1 billion.

Genesis Unicorn Capital plans to list on the Nasdaq under the symbol GENQU. EF Hutton acted as sole bookrunner on the deal.